Voximetry is pleased to welcome Dr. Richard Wahl as Chair of the Scientific & Clinical Advisory Board for the company. Dr. Wahl was among the first to precisely target internal radiation therapy to cancers and has a successful track record of innovation from pre-clinical research to the clinic. His significant translational success includes 20 patents, 2 FDA approved cancer treatments and at least 3 FDA approved devices. He has a long-standing interest in quantitative imaging of cancer and its response to therapy as well as an ongoing interest in radiopharmaceutical therapies of cancer.
Dr. Wahl has received numerous awards, including the 2018 Georg Charles de Hevesy Award from the Society of Nuclear Medicine and Molecular Imaging, where he served as president in 2021/22. He is an elected member of the American Society for Clinical Investigation, the American Association of Physicians and the National Academy of Medicine. A fellow of the American College of Radiology, Wahl holds 18 radiology patents and has published more than 500 peer-reviewed scientific manuscripts. He completed a research fellowship in immunology and earned his medical degree from the Washington University School of Medicine.
As Director of the Mallinckrodt Institute of Radiology at Washington University School of Medicine, Head of the Department of Radiology, and a Professor of Radiation Oncology, Dr. Wahl remains active in developing and testing new radiopharmaceutical therapies of cancer and in integrating them into cancer treatment regimens. We look forward to his sage advice as Voximetry grows and develops solutions in Theranostics.